According to Zhitong Finance App News, Rongchang Biotech (09995.HK) issued an announcement. In order to further enrich the product portfolio of the two parties in the field of global autoimmunity under the license agreement and accelerate the international development of the company's innovation pipeline, on November 12, 2026, the company and Vor Bio signed a revised license agreement (revised agreement) to include the company's RC298 (licensed product) with independent intellectual property rights in the scope of cooperation. Vor Bio will be distributed globally (excluding Greater China (that is, mainland China, Hong Kong, Macau and Taiwan) ) (License area) Exclusive right to develop and commercialize RC298.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.